Testosterone and cardiovascular disease risk

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 22, Issue 3, 2015, Pages 193-202

  Yeap, Bu B ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FIONA STANLEY HOSPITAL   (Australia)

Author keywords

cardiovascular disease; dihydrotestosterone; male ageing; mortality; testosterone

Indexed keywords

ANDROGEN; ANDROSTANOLONE; BIOLOGICAL MARKER; TESTOSTERONE;

ADVERSE OUTCOME; AGING; ANDROGEN THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DRUG SAFETY; EPIDEMIOLOGY; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); MORTALITY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CHEMICALLY INDUCED; DRUG EFFECTS; MALE; METABOLISM;

AGING; CARDIOVASCULAR DISEASES; HUMANS; MALE; TESTOSTERONE;

EID: 84928524534     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000161     Document Type: Review

References (68)

1. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001; 86:724-731.
2. FeldmanHA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002; 87:589-598.
3. Sartorius G, Spasevska S, Idan A, et al. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: The healthy man study. Clin Endocrinol 2012; 77:755-763.
4. Frost M, Wraae K, Nielsen TL, et al. Similar reference intervals for total testosterone in healthy young and elderly men: results from the Odense Androgen Study. Clin Endocrinol 2013; 78:743-751.
5. Shi Z, Araujo AB, Martin S, et al. Longitudinal changes in testosterone over five years in community-dwelling men. J Clin Endocrinol Metab 2013; 98:3289-3297.
6. Sikaris K, McLachlan RI, Kazlauskas R, et al. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab 2005; 90:5928-5936.
7. Yeap BB, Alfonso H, Chubb SAP, et al. Reference ranges and determinants of testosterone, dihydrotestosterone and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men. J Clin Endocrinol Metab 2012; 97:4030-4039.
8. Brand JS, Rovers MM, Yeap BB, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: An individual participant data meta-analysis of observational studies. PLoS One 2014; 9:e100409.
9. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes. J Am Med Assoc 2006; 295: 1288-1299.
10. Araujo AB, Dixon JM, Suarez EA, et al. Endogenous testosterone and mortality in men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96:3007-3019.
11. Cunningham GR, Toma SM. Why is androgen replacement in males controversial? J Clin Endocrinol Metab 2011; 96:38-52.
12. Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust 2013; 199:548-551.
13. Layton JB, Li D, Meier CR, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab 2014; 99:835-842.
14. Lakshman KM, Kaplan B, Travison TG, et al. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab 2010; 95:3955-3964.
15. Jasuja GK, Travison TG, Davda M, et al. Age trends in estradiol and estrone levels measured using liquid chromatography tandem mass spectrometry in community-dwelling men of the Framingham Heart Study. J Gerontol Med Sci 2013; 68:733-740.
16. Handelsman DJ, Wartofsky L. Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism. J Clin Endocrinol Metab 2013; 98:3971-3973;
17. Subsequent comment in Wierman ME, et al. J Clin Endocrinol Metab 2014; 99:4375.
18. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84:3666-3672.
19. Ly LP, Sartorius G, Hull L, et al. Accuracy of calculated free testosterone formulae in men. Clin Endocrinol 2010; 73:382-388.
20. Smith GD, Ben-Shlomo Y, Beswick A, et al. Cortisol, testosterone, and coronary heart disease. Prospective evidence from the Caerphilly Study. Circulation 2005; 112:332-340.
21. Arnlov J, Pencina MJ, Amin S, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med 2006; 145:176-184.
22. Abbott RD, Launer LJ, Rodriguez BL, et al. Serum estradiol and risk of stroke in elderly men. Neurology 2007; 68:563-568.
23. Vikan T, Schirmer H, Njolstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: The Tromso study. Eur J Endocrinol 2009; 161:435-442.
24. Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 2009; 94:2353-2359.
25. Hyde Z, Norman PE, Flicker L, et al. Elevated luteinizing hormone predicts ischaemic heart disease events in older men. The Health in Men Study. Eur J Endocrinol 2011; 164:569-577.
26. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. J Am Coll Cardiol 2011; 58:1674-1681.
27. Haring R, Teng Z, Xanthakis V, et al. Associations of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and allcause mortality in elderly men from the Framingham Heart Study. Clin Endocrinol 2013; 78:629-634.
28. Soisson V, Brailly-Tabard S, Helmer C, et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: The French 3C Cohort Study. Maturitas 2013; 75:282-288.
29. Shores MM, Biggs ML, Arnold AM, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab 2014; 99:2061-2068.
30. Shores MM, Arnold AM, Biggs ML, et al. Testosterone and dihydrotestosterone and incident ischaemic stroke in men in the Cardiovascular Health Study. Clin Endocrinol 2014; 81:746-753.
31. Yeap BB, Alfonso H, Chubb SAP, et al. In older men, higher plasma testosterone or dihydrotestosterone are independent predictors for reduced incidence of stroke but not myocardial infarction. J Clin Endocrinol Metab 2014; 99:4565-4573
32. Kim JS, Nah H-W, Park SM, et al. Risk factors and stroke mechanisms in atherosclerotic stroke. Stroke 2012; 43:3313-3318.
33. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166:1660-1665.
34. Khaw K-T, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men. European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007; 116:2694-2701.
35. Araujo AB, Kupelian V, Page ST, et al. Sex steroids and cause-specific mortality in men. Arch Intern Med 2007; 167:1252-1260.
36. Maggio M, Lauretani F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men. Arch Intern Med 2007; 167:2249-2254.
37. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93:68-75.
38. Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 2009; 94:2482-2488.
39. Szulc P, Claustra B, Delmas PD. Serum concentrations of 17b-E2 and 25-hydroxycholecalciferol (25OHD) in relation to all-cause mortality in older men: The MINOS study. Clin Endocrinol 2009; 71:594-602.
40. Menke A, Guallar E, Rohrmann S, et al. Sex steroid concentrations and risk of death in US men. Am J Epidemiol 2010; 171:583-592.
41. Haring R, Volzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010; 31:1494-1501.
42. Hyde Z, Norman PE, Flicker L, et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: The Health In Men Study. J Clin Endocrinol Metab 2012; 97:179-189.
43. Yeap BB, Alfonso H, Chubb SAP, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality, and higher dihydrotestosterone with reduced ischaemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab 2014; 99:E9-E18.
44. Pye SR, Huhtaniemi IT, Finn JD, et al. Late-onset hypogonadism and mortality in ageing men. J Clin Endocrinol Metab 2014; 99:1357-1366.
45. Anawalt BD. Is men's health just a single letter? J Clin Endocrinol Metab 2014; 99:70-72.
46. English KM,Steeds RP,Hugh Jones T, et al.Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. A randomized, double-blind, placebo-controlled study. Circulation 2000; 102:1906-1911.
47. Mathur A, Malkin C, Saeed B, et al. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol 2009; 161:443-449.
48. Cornoldi A, Caminiti G, Marazzi G, et al. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol 2010; 142:50-55.
49. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. New Engl J Med 2010; 363:109-122.
50. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: A randomized, double-blind, placebocontrolled study. J Clin Endocrinol Metab 2010; 95: 639-650.
51. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: A systematic review and meta-analysis of randomized placebocontrolled trials. Mayo Clin Proc 2007; 82:29-39.
52. Fernandez-Balsells MM, Murad MH, Lane M, et al. Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95:2560-2575.
53. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: A systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013; 11:108.
54. Ruige JB, Ouwens DM, Kaufman J-M. Beneficial and adverse effects of testosterone on the cardiovascular system in men. J Clin Endocrinol Metab 2013; 98:4300-4310.
55. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: A systematic review and meta-analysis. Expert Opin Drug Saf 2014; 13:1327-1351.
56. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009; 169:1756-1761.
57. Ioannidis J, Patsopoulos N, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. Br Med J 2007; 335:914-916.
58. Engels EA, Schmid CH, Terrin N, et al. Heterogeneity and statistical significance in meta-analysis: An empirical study of 125 meta-analyses. Statist Med 2000; 19:1707-1728.
59. FDA Drug Safety Communication. FDA cautions about using testosterone products for low testosterone due to aging; requires labelling change to inform of possible increased risk of heart attack and stroke with use. http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm. [Accessed March 2015
60. Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012; 97:2050-2058.
61. Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013; 169:725-733.
62. Vigen R, O'Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. J Am Med Assoc 2013; 310:1829-1836.
63. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of nonfatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9:e85805.
64. Baillargeon J, Urban RJ, Kuo Y-F, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother 2014; 48:1138-1144.
65. Wu FCW. Caveat emptor: does testosterone treatment reduce mortality in men? J Clin Endocrinol Metab 2012; 97:1884-1886.
66. Traish AM, Guay AT, Morgentaler A. Death by testosterone? We think not! J Sex Med 2014; 11:624-629.
67. Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. September 17, 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM418144.pdf. [Accessed March 2015
68. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:2536-2559.